Iloperidone metabolite for use in the treatment of psychiatric disorders

Abstract

R-P88 is used for the treatment of disorders amenable to treatment with an atypical antipsychotic.

What is claimed is: 
     
         1 . A method of treating a patient suffering from a psychiatric disorder that comprises internally administering to the patient an effective amount of R-P88, or a pharmaceutically acceptable salt thereof, or an ester of R-P88 or a pharmaceutically acceptable salt of such ester, once per day. 
     
     
         2 . The method of  claim 1  wherein the disorder is one that is amenable to treatment with iloperidone. 
     
     
         3 . The method of  claim 1  wherein the disorder is one or more of schizophrenia, schizoaffective disorder, bipolar disorder, (mania and/or depression), depression, major depression, psychotic episodes, autism, autism spectrum disorder, fragile X syndrome, and pervasive developmental disorder. 
     
     
         4 . The method of  claim 1 , wherein the R-P88, or the pharmaceutically acceptable salt thereof or the ester of R-P88 or the pharmaceutically acceptable salt of such ester, is orally administered at a dose of 1 to 24 mg once per day. 
     
     
         5 . The method of  claim 1 , wherein the R-P88, or the pharmaceutically acceptable salt thereof or the ester of R-P88 or the pharmaceutically acceptable salt of such ester, is orally administered at a dose of 12 to 24 mg once per day. 
     
     
         6 . The method of  claim 1 , wherein the R-P88, or the pharmaceutically acceptable salt thereof or the ester of R-P88 or the pharmaceutically acceptable salt of such ester, is orally administered without titration. 
     
     
         7 . A method of treating a patient suffering from a psychiatric disorder that comprises internally administering to the patient an effective amount of R-P88, or a pharmaceutically acceptable salt thereof or an ester of R-P88 or a pharmaceutically acceptable salt of such ester, twice per day without titration. 
     
     
         8 . The method of  claim 7 , wherein the disorder is one that is amenable to treatment with iloperidone. 
     
     
         9 . The method of  claim 7 , wherein the effective amount is selected from:
 1 to 24 mg/day administered twice per day (i.e., 0.5 to 12 mg b.i.d.).   2 to 18 mg/day administered twice per day (i.e., 1 to 9 mg b.i.d.).   2 to 12 mg/day administered twice per day (i.e., 1 to 6 mg b.i.d.).   2 to 10 mg/day administered twice per day (i.e., 1 to 5 mg b.i.d.).   
     
     
         10 . A pharmaceutical composition comprising R-P88 or a pharmaceutically acceptable salt thereof, or an ester of R-P88 or a pharmaceutically acceptable salt of an ester of R-P88, and a pharmaceutically acceptable carrier. 
     
     
         11 . The pharmaceutical composition of  claim 10 , formulated for administration once per day. 
     
     
         12 . The pharmaceutical composition of  claim 10 , formulated for administration twice per day.